These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26165756)

  • 1. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo antibacterial activity and pharmacological properties of the membrane-active glycopeptide antibiotic YV11455.
    Yarlagadda V; Konai MM; Manjunath GB; Prakash RG; Mani B; Paramanandham K; Ranjan SB; Ravikumar R; Chakraborty SP; Roy S; Haldar J
    Int J Antimicrob Agents; 2015 Jun; 45(6):627-34. PubMed ID: 25900818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
    Van Bambeke F
    Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
    Jame W; Basgut B; Abdi A
    PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
    Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
    Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycopeptides: Update on an old successful antibiotic class.
    Pace JL; Yang G
    Biochem Pharmacol; 2006 Mar; 71(7):968-80. PubMed ID: 16412985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of oritavancin and related glycopeptide antibiotics.
    Allen NE; Nicas TI
    FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
    Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.